ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025
Pharmacological evaluation of phage-antibiotic synergism against clinical isolates of multi-drug resistant Staphylococcus aureus in a burn-induced infection mouse model.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistant Staphylococcus aureus (MDRSA) is a superbug that shows enormous resistance to many antibiotics. Identified by the World Health Organization as one of the high priority pathogens, there is an urgent need to develop new antibiotic strategies against MDRSA. One such approach is the use of bacteriophages as antimicrobial agents. When bacteriophages are used in combination with antibiotics, phage-antibiotic synergism (PAS) effectively inhibits bacteria. The current study evaluated various phage-antibiotic combinations to determine the optimal PAS activity against 10 clinical isolates of MDRSA, both in vitro and in a burn-induced wound infection mouse model (n = 3/ group). A novel phage, SDAH-01, was isolated locally and characterized. After establishing in vitro antibacterial activity, a burn-induced skin infection mouse model was used to evaluate PAS activity. Wound contraction, bacterial load, and histopathological changes were observed over the duration of treatment. Inflammatory markers (IL-6, TNF-α, VEGF) were evaluated using immunohistochemical methods. Optimal combinations of phages with amoxicillin, azithromycin, and ciprofloxacin significantly inhibited bacterial growth and promoted wound healing as compared to monotherapies. By Day 14, phage-amoxicillin resulted in a 6-log reduction in bacterial load, showing the maximum activity. Similarly, phage-azithromycin and phage-ciprofloxacin combinations showed significant reductions in comparison to monotherapies depicting their improved efficacy. Phage-antibiotic groups also exhibited highest rates of wound contraction, with phage-amoxicillin and phage-azithromycin demonstrating 55% and 50% contraction respectively. Histological analysis indicated improved tissue regeneration and reduced inflammation with combination therapy. This study demonstrates the potential of PAS in effective management of MDRSA infections, suggesting its potential clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.